Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial

Autor: Hadiza Saidu, Kamilu M. Karaye, Idris Y. Mohammed, Bushra Sanni, Naser A. Ishaq, Haruna Abubakar, Baba Lawan Mohammed, Suleiman A. Balarabe, Tijjani Abdulsalam, Jamilu Tukur
Jazyk: angličtina
Rok vydání: 2020
Předmět:
lcsh:Diseases of the circulatory (Cardiovascular) system
Time Factors
Peripartum cardiomyopathy
030204 cardiovascular system & hematology
Gastroenterology
Ventricular Function
Left
0302 clinical medicine
Pregnancy
Selenium deficiency
Cardiac and Cardiovascular Systems
Prospective Studies
030212 general & internal medicine
Selenomethionine
Kardiologi
Ejection fraction
Hazard ratio
Cardiac surgery
Treatment Outcome
Female
Cardiomyopathies
Cardiology and Cardiovascular Medicine
Research Article
Adult
medicine.medical_specialty
PEACE registry
chemistry.chemical_element
Nigeria
Outcomes
Proof of Concept Study
Selenium
Young Adult
03 medical and health sciences
Selenium supplementation
Internal medicine
Peripartum Period
medicine
Humans
Mortality
Heart Failure
business.industry
Correction
Stroke Volume
Puerperal Disorders
medicine.disease
Confidence interval
chemistry
lcsh:RC666-701
Heart failure
Dietary Supplements
Deficiency Diseases
business
Zdroj: BMC Cardiovascular Disorders
BMC Cardiovascular Disorders, Vol 20, Iss 1, Pp 1-10 (2020)
ISSN: 1471-2261
Popis: Background We studied the efficacy and safety of selenium supplementation in patients who had peripartum cardiomyopathy (PPCM) and selenium deficiency. Methods We randomly assigned 100 PPCM patients with left ventricular ejection fraction (LVEF) Results Over a median of 19 months, the primary outcome occurred in 36 of 46 patients (78.3%) in the selenium group and in 43 of 54 patients (79.6%) in the control group (hazard ratio [HR] 0.69; 95% confidence interval [CI] 0.43–1.09; p = 0.113). Persistence of HF symptoms occurred in 18 patients (39.1%) in the selenium group and in 37 patients (68.5%) in the control group (HR 0.53; 95% CI 0.30–0.93; p = 0.006). LVEF p = 0.944). Death from any cause occurred in 3 patients (6.5%) in the selenium group and in 9 patients (16.7%) in the control group (HR 0.37; 95% CI 0.10–1.37; p = 0.137). Conclusions In this study, selenium supplementation did not reduce the risk of the primary outcome, but it significantly reduced HF symptoms, and there was a trend towards a reduction of all-cause mortality. Clinical trial registration ClinicalTrials.gov Identifier: NCT03081949.
Databáze: OpenAIRE
Externí odkaz: